Depo-Provera Contraceptive Injection - DP150CI

ApprovedCompleted

0 watching 0 views this week🔥 Hot

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

Contraception

Conditions

Contraception, Bone Density

Trial Timeline

Apr 1, 1998 → Jul 1, 2007

NCT ID

NCT00139685

About Depo-Provera Contraceptive Injection - DP150CI

Depo-Provera Contraceptive Injection - DP150CI is a approved stage product being developed by Pfizer for Contraception. The current trial status is completed. This product is registered under clinical trial identifier NCT00139685. Target conditions include Contraception, Bone Density.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00139685	Approved	Completed	Apr 1, 1998	Jul 1, 2007	Contraception

Competing Products

20 competing products in Contraception

See all competitors

Product	Company	Stage	Hype Score
Injection Cyclofem	Sun Pharmaceutical	Phase 1/2	41
Relugolix Combination Therapy	Sumitomo Pharma	Phase 3	77
Transdermal Contraceptive System + Norgestimate-containing oral contraceptives with EE	Johnson & Johnson	Pre-clinical	23
norelgestromin/ethinyl estradiol (NGMN/EE) transdermal contraceptive system.	Johnson & Johnson	Phase 1	33
norelgestromin + ethinyl estradiol	Johnson & Johnson	Phase 3	77
norelgestromin + ethinyl estradiol; triphasil.	Johnson & Johnson	Phase 3	77
norelgestromin + ethinyl estradiol; mercilon	Johnson & Johnson	Phase 3	77
EVRA® transdermal contraceptive patch containing 6 mg of norelgestromin and 0.60 mg of ethinyl estradiol (versus CILEST® tablets).	Johnson & Johnson	Phase 1	33
EVRA transdermal contraceptive patch 6 mg NGMN and 0.75 mg EE	Johnson & Johnson	Phase 1	33
Monophasic or triphasic Oral contraceptive tablet + Ortho Evra transdermal patch containing 6 mg NGMN/0.75 mg EE	Johnson & Johnson	Pre-clinical	23
Norgestimate/Ehinyl Estradiol; Folic acid.	Johnson & Johnson	Phase 1	33
EVRA® transdermal contraceptive patch containing 6 mg of norelgestromin and 0.75 mg of ethinyl estradiol (versus CILEST® tablets).	Johnson & Johnson	Phase 1	33
oral ulipristal acetate	Merck	Phase 1	33
Etonogestrel contraceptive implant	Merck	Approved	85
Rifampin 600 MG	Merck	Approved	85
Long Acting Reversible Contraception (LARC)	Merck	Approved	85
Etonogestrel contraceptive implant	Merck	Approved	85
Medroxyprogesterone 17-Acetate + Medroxyprogesterone 17-Acetate	Pfizer	Pre-clinical	22
Sayana Press	Pfizer	Approved	84
Levonorgestrel 90 mg/Ethinyl Estradiol 20 mg	Pfizer	Phase 3	76

Other Products from Pfizer